Last reviewed · How we verify
Chlonixin (CLONIXIN)
Chlonixin (generic name: CLONIXIN) is a clonixin drug. It is currently in Phase 2 development.
Chlonixin works by inhibiting the enzyme dihydroorotate dehydrogenase, which is involved in the production of pyrimidine nucleotides.
Chlonixin, also known as CLONIXIN, is a small molecule drug that targets dihydroorotate dehydrogenase (quinone), a mitochondrial enzyme. It belongs to the clonixin drug class and is used to treat certain conditions. However, its commercial status and approved indications are unknown. Further research is needed to determine its safety profile and potential side effects. As a result, it is not currently available on the market.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CLONIXIN |
|---|---|
| Drug class | clonixin |
| Target | Dihydroorotate dehydrogenase (quinone), mitochondrial |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Think of it like a traffic cop: dihydroorotate dehydrogenase helps control the flow of building blocks for DNA and RNA. Chlonixin acts like a roadblock, preventing this enzyme from doing its job. This can help slow down the growth of cells, which can be beneficial in treating certain conditions.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chlonixin CI brief — competitive landscape report
- Chlonixin updates RSS · CI watch RSS
Frequently asked questions about Chlonixin
What is Chlonixin?
How does Chlonixin work?
What is the generic name of Chlonixin?
What drug class is Chlonixin in?
What development phase is Chlonixin in?
What does Chlonixin target?
Related
- Drug class: All clonixin drugs
- Target: All drugs targeting Dihydroorotate dehydrogenase (quinone), mitochondrial
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing